The clinical and biochemical determinants of the fibrinogen response to sim
vastatin or atorvastatin therapy were assessed in 130 patients with severe
polygenic or familial hypercholesterolemia treated in a randomized open-tri
al format design. Hyperfibrinogenemia was associated with atorvastatin, bas
eline fibrinogen, and initial concentration and change in concentration of
apolipoprotein B or low-density lipoprotein cholesterol.